Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotorasib - Amgen

Next Previous
Drug Profile

Sotorasib - Amgen

Alternative Names: AMG-510; LUMAKRAS; LUMYKRAS

Latest Information Update: 12 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Carmot Therapeutics
  • Developer Amgen; BeOne Medicines; REVOLUTION Medicines; Verastem Oncology
  • Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Non-small cell lung cancer
  • Phase III Solid tumours
  • Phase I/II Brain metastases; Pancreatic cancer

Most Recent Events

  • 29 Dec 2025 Verastem Oncology terminates phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in the US, Belgium, France, Netherlands, Spain and United Kingdom (NCT05074810)
  • 15 Sep 2025 Amgen plans a phase-II trial for Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in October 2025 (PO), (NCT07172919)
  • 25 Jul 2025 Launched for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top